Evidence map›Paper›PMID 38847231›Full record

ArticleInternational journal of oncology2024

Significance of signal recognition particle 9 nuclear translocation: Implications for pancreatic cancer prognosis and functionality.

Hiromichi Sato, Sikun Meng, Kazuki Sasaki, Shogo Kobayashi, Kansuke Kido, Yoshiko Tsuji, Yasuko Arao, Yoshiko Saito, Yoshifumi Iwagami, Daisaku Yamada and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Hiromichi Sato *Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Sikun Meng *Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Kazuki SasakiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Shogo KobayashiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Kansuke KidoDepartment of Pathology, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Yoshiko TsujiDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Yasuko AraoDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Yoshiko SaitoDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Yoshifumi IwagamiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Daisaku YamadaDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Yoshito TomimaruDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Takehiro NodaDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Hidenori TakahashiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Daisuke MotookaGenome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka 565‑0871, Japan.
Shizuka UchidaCenter for RNA Medicine, Department of Clinical Medicine, Aalborg University, DK‑2450 Copenhagen, Denmark.
Ken OfusaDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Taroh SatohDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Hidetoshi EguchiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Tomoaki HaraDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.
Hideshi IshiiDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Osaka 565‑0871, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Signal recognition particles (SRPs) are essential for regulating intracellular protein transport and secretion. Patients with tumors with high SRP9 expression tend to have a poorer overall survival. However, to the best of our knowledge, no reports have described the relationship between SRP9 localization and prognosis in pancreatic cancer. Thus, the present study aimed to investigate this relationship. Immunohistochemical staining for SRP9 using excised specimens from pancreatic cancer surgery cases without preoperative chemotherapy or radiotherapy showed that SRP9 was preferentially expressed in the nucleus of the cancerous regions in some cases, which was hardly detected in other cases, indicating that SRP9 was transported to the nucleus in the former cases. To compare the prognosis of patients with SRP9 nuclear translocation, patients were divided into two groups: Those with a nuclear translocation rate of >50% and those with a nuclear translocation rate of ≤50%. The nuclear translocation rate of >50% group had a significantly better recurrence‑free survival than the nuclear translocation rate of ≤50% group (P=0.037). Subsequent

Indexed as

Cell NucleusPancreatic NeoplasmsSignal Recognition ParticleActive Transport, Cell NucleusAdultAgedCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisSerine-Arginine Splicing FactorsSerine-Arginine Splicing FactorsSignal Recognition ParticleSRP9 protein, humanessential amino acidsnuclear translocationpancreatic cancersignal recognition particle 9splicing variants

Identifiers

PMID38847231
PMCPMC11173368

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.